Mark Kris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5897505/publications.pdf

Version: 2024-02-01

10 papers	6,187	1307594 7 h-index	1474206 9 g-index
papero	Citations	II IIICA	g muca
10 all docs	10 docs citations	10 times ranked	7289 citing authors

#	Article	IF	CITATIONS
1	EGF receptor gene mutations are common in lung cancers from "never smokers―and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13306-13311.	7.1	4,106
2	Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	30.7	1,015
3	ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial. Journal of Clinical Oncology, 2002, 20, 2240-2250.	1.6	750
4	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205
5	Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Supportive Care in Cancer, 2013, 21, 1735-1741.	2.2	56
6	The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. Cancer, 1999, 86, 1720-1723.	4.1	34
7	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	1.8	12
8	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. Neuro-Oncology Advances, 2021, 3, vdab181.	0.7	8
9	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 247-251.	1.3	1
10	New approaches in the management of lung cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S22-4.	4.9	0